Live Breaking News & Updates on Developmental Therapeutics Branch

Stay updated with breaking news from Developmental therapeutics branch. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Transformation-associated recombination (TAR) cloning and its applications

Transformation-associated recombination (TAR) cloning and its applications
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Vladimir Larionov , Natalay Kouprina , National Cancer Institute Developmental Therapeutics Branch , National Cancer Institute , Developmental Therapeutics Branch ,

Drug combination provides a one-two punch attack against colorectal cancer

Drug combination provides a one-two punch attack against colorectal cancer
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Yves Pommier , Yilun Sun , Translational Sciences , Nature Communications , Developmental Therapeutics Branch , National Center , Developmental Therapeutics , Advancing Translational Sciences ,

Lantern Pharma Expands Precision Oncology Collaboration with the National Cancer Institute - Accelerating Path to First in Human Clinical Trials for Drug Candidates LP-184 & LP-284

/PRNewswire/ Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform. ....

United States , Kishor Bhatia , Broad Institute , National Cancer Institute , Exchange Commission On , National Institutes Of Health , Drug Administration , Society Of Neuro , Developmental Therapeutics Branch , Securities Exchange , Lantern Pharma , National Institutes , Glioblastoma Multiforme , Chief Scientific Officer , Pharmacology Facility , Project Achilles , Panna Sharma , Drug Designation , Response Algorithm , Drug Positioning , Securities Act , Securities Exchange Act , Risk Factors , Annual Report , Exchange Commission ,

Merck Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Registrational Intent

Merck Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Registrational Intent
1
A new company-sponsored, global clinical trial will further assess berzosertib in small cell lung cancer
Merck is leading more than ten clinical trials across DNA Damage Response (DDR) pathways in various tumor types
Merck, a leading science and technology company, today announced key clinical advancements for berzosertib (M6620), an investigational, potent and selective ataxia telangiectasia and Rad3-related (ATR) inhibitor. Berzosertib is the leading asset in the company s DNA damage response (DDR) inhibitor program and one of the most advanced ATR inhibitors in oncology clinical development industry-wide. ....

United States , Danish Thomas , Julissa Viana , National Cancer Institute , Lasker Clinical Research Scholar , Cancer Research , Merck Kga , Developmental Therapeutics Branch , American Cancer Society , Vertex Pharmaceuticals , Development Agreement , National Institutes Of Health , Merck Press , American Cancer Society Small Cell Lung , Us National Cancer Institute , Global Head Of Development For The Healthcare , Merck Kgaa , Cancer Institute , Cancer Cell , Clinical Research Scholar , National Institutes , Cooperative Research , Danny Bar Zohar , Global Head , Lancet Oncology , Clinical Trials ,